Online inquiry

IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12676MR)

This product GTTS-WQ12676MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets FZD1&FZD2&FZD5&FZD7&FZD8 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003505.2; NM_001466.4; NM_003468.4; NM_003507; NM_031866.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8321; 2535; 7855; 8324; 8325
UniProt ID Q9UP38; Q14332; Q13467; O75084; Q9H461
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12676MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5015MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA c4G7-N
GTTS-WQ793MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ2616MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 557
GTTS-WQ580MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ11543MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGA031
GTTS-WQ6948MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ5093MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ12030MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MM-302
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW